FY2025 EPS Estimate for Wave Life Sciences Raised by Analyst

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for Wave Life Sciences in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will post earnings of ($1.07) per share for the year, up from their previous forecast of ($1.09). Cantor Fitzgerald has a "Overweight" rating and a $10.00 price objective on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share.

A number of other equities analysts have also recently issued reports on WVE. Jefferies Financial Group assumed coverage on shares of Wave Life Sciences in a research report on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Wedbush began coverage on shares of Wave Life Sciences in a research report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 target price on the stock. Finally, StockNews.com cut shares of Wave Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $21.17.

Wave Life Sciences Stock Performance

Shares of NASDAQ:WVE traded down $0.03 during midday trading on Wednesday, reaching $6.30. The company's stock had a trading volume of 233,777 shares, compared to its average volume of 1,280,910. The firm has a market capitalization of $970.89 million, a price-to-earnings ratio of -5.66 and a beta of -0.92. The firm has a 50 day moving average price of $7.42 and a two-hundred day moving average price of $10.85. Wave Life Sciences has a fifty-two week low of $4.25 and a fifty-two week high of $16.74.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). The business had revenue of $9.18 million during the quarter, compared to analyst estimates of $11.65 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. During the same period in the prior year, the firm earned ($0.24) earnings per share.

Insider Activity

In other news, CEO Paul Bolno sold 169,025 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares of the company's stock, valued at approximately $3,238,019.07. This represents a 33.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christian O. Henry sold 10,500 shares of the company's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the transaction, the director now directly owns 16,115 shares of the company's stock, valued at approximately $157,443.55. This trade represents a 39.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 29.10% of the company's stock.

Hedge Funds Weigh In On Wave Life Sciences

Institutional investors have recently bought and sold shares of the stock. Moody Aldrich Partners LLC increased its stake in shares of Wave Life Sciences by 31.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company's stock valued at $4,929,000 after purchasing an additional 95,413 shares in the last quarter. Arizona State Retirement System boosted its holdings in Wave Life Sciences by 34.2% in the fourth quarter. Arizona State Retirement System now owns 30,769 shares of the company's stock worth $381,000 after purchasing an additional 7,846 shares during the last quarter. Corebridge Financial Inc. boosted its holdings in Wave Life Sciences by 10.7% in the fourth quarter. Corebridge Financial Inc. now owns 45,824 shares of the company's stock worth $567,000 after purchasing an additional 4,423 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Wave Life Sciences by 10.2% in the fourth quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company's stock worth $39,368,000 after purchasing an additional 294,956 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in Wave Life Sciences in the fourth quarter worth approximately $3,076,000. 89.73% of the stock is owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.